Market News & Trends
Global Non-Small Cell Lung Cancer Treatment Market Value to Approach $11 Billion
The global market value for Non-Small Cell Lung Cancer (NSCLC) treatment will increase from $6.9 billion in 2014 to $10.9 billion by 2021, representing a…
Glenmark Pharmaceuticals' Novel Monoclonal Antibody to Enter Phase II
Glenmark Pharmaceuticals S.A. recently announced that GBR 830, a novel monoclonal antibody has completed clinical Phase I dosing. GBR 830 is an antagonist of OX40,…
Chugai Pharmaceutical’s Bispecific Antibody Designated as Breakthrough Therapy
Chugai Pharmaceutical Co., Ltd. recently announced today the US FDA has granted the Breakthrough Therapy Designation to ACE910 for the prophylactic treatment of people who…
Alvogen Launches First Generic Exelon Patch in the US
Alvogen recently announced it has launched the first generic equivalent of Exelon patch (rivastigmine transdermal system) in the US. The product will be marketed by…
Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells
Batu Biologics has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation…
Follica Announces Allowance for US Patent Related to Platform for Hair Loss
Follica Inc. recently received confirmation of an issue notification from the United States Patent and Trademark Office (USPTO) regarding the company’s principal technology platform. The…
Bristol-Myers Squibb & Promedior Enter Exclusive Agreement
Bristol-Myers Squibb Company and Promedior, Inc. recently announced they have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and…
Branded Acute Coronary Syndrome Therapies to Grab Market Share From Generic Drugs Globally
The acute coronary syndrome (ACS) therapeutics market consists of approximately 30 marketed branded drugs and hundreds of generics. While generic ACS drugs currently lead in…
Antisense RNAi Therapeutics Deals Value Approached $5.6 Billion in Landmark 2014
The deals market for antisense RNA interference (RNAi) therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59…
Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project
Generex Biotechnology Corporation recently provided an update on the status of the buccal insulin formulation enhancement project for the company's proprietary Generex Oral-lyn buccal insulin…
CoreRx, Inc. Increasing Capacity With Construction of Third Facility
CoreRx, Inc. recently announced plans for expansion of its manufacturing capabilities in Clearwater, FL. The expansion will introduce a third facility to include additional R&D…
MorphoSys & Immatics Biotechnologies Enter Strategic Alliance
MorphoSys AG and Immatics Biotechnologies GmbH recently announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.…
Dauntless Pharmaceuticals & Aegis Therapeutics Announce Licensing Agreement
Dauntless Pharmaceuticals, Inc. and Aegis Therapeutics, LLC recently announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology…
Corium Receives US Patent for Dissolving “Drug-in-Tip” MicroCor Transdermal Patches
Corium recently announced the issuance of a patent relating the company’s unique dissolving “Drug-in-Tip” MicroCor transdermal patch, which enables the needle-free delivery of biologics, vaccines,…
QB3@953 Signs Collaboration Agreement With GlaxoSmithKline
QB3@953a San Francisco incubator created by QB3, a University of California (UC) research institute and biotech accelerator, recently announced an agreement with pharmaceutical company GSK…
Cell Culture & Upstream Processing - BioProcess International Conference Pre-Event Podcast Series
Development of a Scaleable and Productive Insect Cell Culture Based Process for Making Flublok, The First FDA Licensed Recombinant Influenza Vaccine Barry Buckland, Senior Advisor,…
Life Cycle Management Strategies More Crucial than Ever for Pharmaceutical Success
With shrinking Research and Development (R&D) pipelines and mounting costs involved in drug development, it is becoming increasingly important for pharmaceutical companies to implement suitable…
VBL Announces First Patient Dosed In Pivotal Phase III Trial
VBL Therapeutics recently announced that the first patient has been dosed in the company's GLOBE Study, a pivotal Phase III trial of VB-111, an intravenously…
Janus Biotherapeutics Enters Collaboration With Roche
Janus Biotherapeutics recently announced it has entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the…
Presage Biosciences Receives Strategic Investment from Takeda
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, recently…
